Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,529 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab for treating patients with occupational cholangiocarcinoma.
Tanaka S, Umemoto K, Kubo S, Sato Y, Mimaki S, Tsuchihara K, Takemura S, Shinkawa H, Mori A, Ikeda M. Tanaka S, et al. Among authors: ikeda m. J Hepatobiliary Pancreat Sci. 2022 Nov;29(11):1153-1155. doi: 10.1002/jhbp.1215. Epub 2022 Aug 8. J Hepatobiliary Pancreat Sci. 2022. PMID: 35793385
Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.
Ikeda M, Sato A, Mochizuki N, Toyosaki K, Miyoshi C, Fujioka R, Mitsunaga S, Ohno I, Hashimoto Y, Takahashi H, Hasegawa H, Nomura S, Takahashi R, Yomoda S, Tsuchihara K, Kishino S, Esumi H. Ikeda M, et al. Cancer Sci. 2016 Dec;107(12):1818-1824. doi: 10.1111/cas.13086. Epub 2016 Dec 19. Cancer Sci. 2016. PMID: 27685612 Free PMC article. Clinical Trial.
Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer.
Fujioka R, Mochizuki N, Ikeda M, Sato A, Nomura S, Owada S, Yomoda S, Tsuchihara K, Kishino S, Esumi H. Fujioka R, et al. Among authors: ikeda m. PLoS One. 2018 Jun 1;13(6):e0198219. doi: 10.1371/journal.pone.0198219. eCollection 2018. PLoS One. 2018. PMID: 29856804 Free PMC article. Clinical Trial.
Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors.
Imaoka H, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, Watanabe K, Umemoto K, Kimura G, Suzuki Y, Kan M, Ikeda M. Imaoka H, et al. Among authors: ikeda m. Oncologist. 2019 Jan;24(1):47-53. doi: 10.1634/theoncologist.2017-0651. Epub 2018 Aug 2. Oncologist. 2019. PMID: 30072388 Free PMC article. Clinical Trial.
Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy.
Suzuki Y, Kan M, Kimura G, Umemoto K, Watanabe K, Sasaki M, Takahashi H, Hashimoto Y, Imaoka H, Ohno I, Mitsunaga S, Ikeda M. Suzuki Y, et al. Among authors: ikeda m. J Gastroenterol. 2019 Mar;54(3):281-290. doi: 10.1007/s00535-018-1518-3. Epub 2018 Oct 8. J Gastroenterol. 2019. PMID: 30298469 Free PMC article. Clinical Trial.
6,529 results